Corrected: Weekly Market Movers: Global Majors & Industry (to 15 Sep 2017)

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations.

Detailing the previous week’s top 10 market gains and losses, aligned with significant news flow driving share prices, the EventAnalyzer keeps you in touch with the latest market moves.

The analysis now includes a look at the share price performance of large cap companies.

Correction: the comments for Achillion were incorrectly attributed to Nabriva, this has been amended.

Top 10 Gains (%) - ranked on change in share price

Performance: Fri 15 Sep vs. Fri 08 Sep
Rank Company Listed   Currency Share Price   Change Market Cap   (US$m) Market Cap   Change Notes on Change
1 Mirati Therapeutics CAD +124% 280 +155 14 Sep [Post market]: Company reports positive interim phase II results of its NSCLC treatment sitravatinib in combination with Opdivo.
2 Aldeyra Therapeutics USD +114% 135 +72
3 Fennec Pharmaceuticals USD +60% 188 +71 13 Sep: Company announces positive preliminary results from its Siopel 6 study on sodium thiosulfate, to be presented at SIOP 2017 next month.
4 Verona Pharma GBP +26% 251 +53
5 Abeona Therapeutics USD +24% 693 +135 14 Sep [Post market]: RBC Capital initiates coverage with an "outperform" rating and price target of $23.
6 Halozyme Therapeutics USD +24% 2306 +445 14 Sep: Company licenses its Enhanze drug delivery technology to Roche for development of an undisclosed therapeutic target for $30m up front and up to $160m in milestones. Company also licenses Enhanze to Bristol-Myers Squibb for development of up to 11 new immuno-oncology drug targets for $105m up front and up to $1.76bn in milestones. Company raises its full-year financial guidance.
7 CymaBay Therapeutics USD +21% 315 +55 11 Sep: EMA grants orphan drug designation to company's primary biliary cholangitis treatment, seladelpar.
8 Teva Pharmaceutical Industries USD +17% 18375 +2639 11 Sep: Company selects Kare Schultz, the current chief executive of Lundbeck, to become its next CEO. 
11 Sep [post market]: Company to sell its ParaGard intrauterine contraceptive device business to Cooper Cos. for $1.1bn.
9 Bellicum Pharmaceuticals USD +17% 389 +55
10 Loxo Oncology USD +14% 2612 +329 13 Sep: Shares rise on 5x average daily trading volume. 
13 Sep: Company presents positive phase I results for its non-small cell lung cancer treatment, LOXO-292, at the IASLC 18th world conference on lung cancer.

Excludes companies with a market cap. movement of less than US$35m & non-Japanese Asian companies.

Top 10 Losses (%) - ranked on change in share price

Performance: Fri 15 Sep vs. Fri 08 Sep
Rank Company Listed   Currency Share Price   Change Market Cap   (US$m) Market Cap   Change Notes on Change
1 Forward Pharma USD -78% 586 -2064 12 Sep: Shares trade ex-dividend. 
13 Sep: Shares fall on 5x average daily trading volume.
2 Onxeo EUR -50% 111 -112
3 Bavarian Nordic DKK -47% 1060 -931 12 Sep: Company's hepatocellular carcinoma treatment Livatag fails to meet its primary endpoint in the ReLive phase III trial on 11 Sep.
4 Santhera Pharmaceuticals CHF -44% 243 -194 14 Sep [post market]: Company's castration-resistant prostate project Prostvac fails its phase III Prospect trial.
5 Advaxis USD -35% 198 -102 15 Sep: EU CHMP adopts negative opinion for company's duchenne muscular dystrophy project Raxone.
6 SAGE Therapeutics USD -28% 2335 -922 11 Sep [post market]: Company reports wider-than-expected Q3'17 losses. 
7 NewLink Genetics USD -28% 373 -147 12 Sep: Company's super-refractory status epilepticus treatment brexanolone fails in a phase III trial. 
14 Sep: BMO Capital reiterates an "outperform" rating and lowers price target to $80 from $84.
8 Achillion Pharmaceuticals USD -25% 506 -165 11 Sep: Johnson & Johnson terminates its development agreement with Achillion for hepatitis C treatment JNJ-4178 on 9 Sep. 
11 Sep: Baird lowers price target to $4 from $5 while maintaining a "neutral" rating after J&J terminated the hep C collaboration. 
9 Nabriva Therapeutics USD -22% 1841 -510
10 Intercept Pharmaceuticals USD -19% 2381 -553 12 Sep: Company issues a letter warning physicians against overdosing some patients with Ocaliva, which has been tied to liver injuries and death.

Excludes companies with a market cap. movement of less than US$35m & non-Japanese Asian companies.

EventAnalyzer Large Cap Movements – Top pharma companies ranked on share price movement

Performance: Fri 15 Sep vs. Fri 08 Sep
Rank Company Listed   Currency Share Price   Change Market Cap   (US$m) Market Cap   Change Notes on Change
1 Teva Pharmaceutical Industries USD +16.8% 18375 +2639 11 Sep: Company selects Kare Schultz, the current chief executive of Lundbeck, to become its next CEO. 
11 Sep [post market]: Company to sell its ParaGard intrauterine contraceptive device business to Cooper Cos. for $1.1bn.
2 Astellas Pharma JPY +5.3% 27085 +1370 14 Sep: Company and partner Pfizer report positive results from its phase III Prosper trial for Xtandi for   treatment of non-metastatic castration-resistant prostate cancer.
3 Amgen USD +3.8% 136792 +4984 11 Sep: Company and partner Allergan  present positive phase III results for breast cancer treatment ABP 980 , a Herceptin biosimilar, at ESMO 2017 on 9 Sep. 
14 Sep: FDA approves Amgen and Allergan's cancer treatment, Mvasi, a biosimilar version of Roche's Avastin.
4 Pfizer USD +3.7% 210298 +7493 11 Sep: Company announce positive results of phase III study of PF-05280014, a Herceptin biosimilar, at ESMO 2017 on 10 Sep; Company announces positive data for the treatment of NSCLC, Xalkori.
14 Sep: Company and partner Astellas Pharma report positive results from its phase III Prosper trial for Xtandi  for treatment of non-metastatic castration-resistant prostate cancer. 
5 Merck & Co USD +2.9% 180442 +5155 11 Sep: Company and partner Incyte present positive phase I/II data from Keynote-037 trial for Keytruda in combination with Incyte's epacadostat at ESMO 2017 on 9 Sep. 
6 Johnson & Johnson USD +2.6% 360864 +9314
7 AbbVie USD +2.4% 139276 +3236 Shares continue to rise after company's upadacitinib (ABT-494) meets primary endpoint in a phase IIb trial in atopic dermatitis. 
8 Takeda JPY +1.6% 43890 +703
9 Bayer EUR +1.5% 97838 +1461 14 Sep [post market]: Company receives FDA approval for selling Aliqopa for the treatment of follicular B-cell non-Hodgkin's lymphoma.
10 Merck KGaA EUR +1.4% 45184 +628
11 Novo Nordisk DKK +1.2% 108235 +1297 13 Sep: Company announce positive result for the treatment of type 2 diabetes, Xultophy.
15 Sep: Company announce positive result for the treatment of type 2 diabetes, Tresiba.
12 Celgene USD +1.1% 111125 +1205
13 AstraZeneca USD +0.9% 82359 +709 11 Sep: Company presents positive phase III results for lung cancer treatments Imfinzi and Tagrisso at   ESMO 2017. 
14 Novartis USD -0.1% 223950 -130
15 Bristol-Myers Squibb USD -0.2% 102463 -229
16 Roche CHF -0.6% 209480 -1878 11 Sep: Company's phase III study of Zelboraf for the adjuvant treatment of people with completely resected BRAF V600 mutation-positive melanoma fails to meet its primary endpoint.
8 Sep [post market]: Company's age-related macular degeneration (AMD) treatment lampalizumab fails to meet its endpoints in a phase III trial.
17 Eli Lilly USD -0.6% 90766 -528
18 Shire USD -1.0% 47976 -490
19 Sanofi EUR -1.0% 110096 -1136 11 Sep: Company and partner Regeneron's asthma drug dupilumab meets primary endpoints in a phase III trial however, data on asthma attack frequencies are less impressive compared to earlier phase II results.
20 Biogen USD -1.6% 67925 -1072
21 GlaxoSmithKline GBP -2.7% 90407 -2487
22 Gilead Sciences USD -3.2% 107556 -3578
23 Allergan USD -5.7% 73644 -4433

Disclaimer:
The above analysis is based on daily share prices supplied to Evaluate Ltd. by a third party. Evaluate Ltd. accepts no responsibility or liability for the accuracy of the data presented here. Neither should any data presented here be construed as a solicitation or offer to buy or sell any securities or related financial instruments.

Share This Article